Oligon

Oligon Therapeutics is a private biotechnology company developing next-generation RNA therapeutics based on its SeekR platform. The company engineers self-delivering oligonucleotide drugs that combine dual RNA aptamer binders with dual siRNA silencers in a single construct to improve cell-selective delivery and enable multi-target RNA interference. Oligon is focused on oncology, immunology, and other complex diseases, with an initial pipeline aimed at reprogramming specific immune cell subtypes and additional partnered programs targeting cancer cells. The company uses AI-enabled molecular modeling to design and optimize receptor-binding oligonucleotide therapeutics. Oligon appears to be operating from Montreal following a 2025 launch backed by CTI Life Sciences Fund and co-investors.